

Pipeline and Upcoming Milestones¹

Vision Care		
Product	Status	Upcoming Milestone
SiHy Daily	Launched in ~25 countries	Launching SVS into more countries in 2022; Multi-focal and toric launch coming 2023-2024
Lacelle® colored contact lenses	Approved in Japan	New range of Daily Disposable cosmetic lens launching in Japan in 2022
Biotrue® Hydration Plus Multi-purpose Solution	Approved (US FDA, Health Canada, NMPA/China)	U.S. launch ongoing; Canada launched 2H22; China launch expected 1H23
Biotrue® PF Contact Lens Rehydrating Drops (Multidose & Single Dose Use)	Design transfer and Commercialization Readiness stage	U.S. FDA submission expected 2022, launch mid-2023
LUMIFY® Line Extensions	Phase 3 study in progress	One phase 3 clinical study started. Additional studies started in 2H22
Myopia control contact lens ²	Myopia control contact lens design licensed from BHVI	Global clinical study to begin in 2023

Pipeline and Upcoming Milestones¹

Surgical		
Product	Status	Upcoming Milestone
enVista Envy™ <i>enVista® Trifocal IOL (Intraocular Lens)</i>	Canadian study completed enrollment in 1Q22; U.S. study completed enrollment in 2Q22	Expect Canadian launch 2023; Expect US and EU launch 2024
StableVisc™ Cohesive OVD	Clinical Study Report completed 2Q22; FDA submission filed early 3Q22	Expect US approval 4Q22
enVista Aspire™ <i>enVista® Extended Range Monofocal IOL</i>	US and Canada submission planned for 4Q22 EU submission planned for 2Q23	Expect US and Canada launch 2H23
enVista Dynamic™ <i>enVista® Extended Depth of Focus IOL</i>	Clinical study to begin 3Q23	Expect 2025/2026 launch
Lux Premium IOL	Launched in Europe	Continued expansion of platform expected in 2023
Next Generation Surgical Platform - System 202x	Alpha prototype build and test underway	Beta prototyping expected 1Q23
eyeTELLIGENCE® Digital Platform	Beta software release at AAO October 2022; Software as Medical Device (SaMD) documentation ongoing	US commercial release expected 1Q23
3D Microscope	Approval expected 2023	Launch expected in 2023
Teneo™ Excimer Laser	Enrollment completed for myopia study Enrolled first patient 3Q22 in hyperopia study	Expected myopia launch in U.S. in 2023

Pipeline and Upcoming Milestones¹

Ophthalmic Pharmaceuticals		
Product	Status	Upcoming Milestone
VYZULTA® geo-expansion	Launched in 15 countries	Expected to launch in ~10 additional countries in 2023+
NOV03 ² (dry eye disease associated with meibomian gland dysfunction)	FDA accepted NDA in September 2022	PDUFA date June 28, 2023
Biosimilar candidate for Lucentis (ranibizumab) ³	Xbrane withdrew aBLA ⁵ after receiving feedback from FDA that supplemental information would be required	Resubmission target date expected by end 2022
Microdose formulation of atropine ophthalmic solution (reduction of pediatric myopia progression in children ages 3-12) ⁴		Clinical trial enrollment completion is delayed from 4Q22 to 1H23 due to clinical trial material availability